Display options
Cite
Hao H, Wang L, Chen H, et al. YKL-40 promotes the migration and invasion of prostate cancer cells by regulating epithelial mesenchymal transition. Am J Transl Res. 2017;9(8):3749-3757
Hao, H., Wang, L., Chen, H., Xie, L., Bai, T., Liu, H., & Wang, D. (2017). YKL-40 promotes the migration and invasion of prostate cancer cells by regulating epithelial mesenchymal transition. American journal of translational research, 9(8), 3749-3757.
Hao, Hailong, et al. "YKL-40 promotes the migration and invasion of prostate cancer cells by regulating epithelial mesenchymal transition." American journal of translational research vol. 9,8 (2017): 3749-3757.
Hao H, Wang L, Chen H, Xie L, Bai T, Liu H, Wang D. YKL-40 promotes the migration and invasion of prostate cancer cells by regulating epithelial mesenchymal transition. Am J Transl Res. 2017 Aug 15;9(8):3749-3757. eCollection 2017. PMID: 28861166; PMCID: PMC5575189.
Copy Download .nbib Format: NLM
Share it on

Am J Transl Res. 2017 Aug 15;9(8):3749-3757. eCollection 2017.

YKL-40 promotes the migration and invasion of prostate cancer cells by regulating epithelial mesenchymal transition.

American journal of translational research

Hailong Hao, Lei Wang, Huiqing Chen, Liwu Xie, Tao Bai, Hongyu Liu, Dongwen Wang

Affiliations

  1. Department of Urology, First Hospital of Shanxi Medical UniversityTaiyuan 030001, Shanxi, China.
  2. Department of Urology, Shanxi Provincial Cancer HospitalTaiyuan 030013, Shanxi, China.
  3. Department of Respiratory Medicine, Shanxi Dayi HospitalTaiyuan 030013, Shanxi, China.
  4. Department of Pathology, Shanxi Provincial Cancer HospitalTaiyuan 030013, Shanxi, China.
  5. Department of Pathology, First Hospital of Shanxi Medical UniversityTaiyuan 030001, Shanxi, China.

PMID: 28861166 PMCID: PMC5575189

Abstract

OBJECTIVE: This study aims to observe the expression of YKL-40 in prostate cancer and whether YKL-40 can affect the migration and invasion of tumor cells by regulating epithelial mesenchymal transition.

METHODS: We collected 14 cases of prostate cancer tissues and adjacent tissues in this study. The expression levels of YKL-40 in the tissues were analyzed by western blotting and immunohistochemical methods. The expression of YKL-40 in human prostate cancer cell line DU145 and PC3 was detected by fluorescence quantitative PCR and western blotting methods. The expression levels of YKL-40 in different cells were up-regulated or down- regulated by lentivirus to observe the changes of cell migration and invasion. The expression levels of EMT related genes were analyzed by RT-PCR and Western blotting methods.

RESULTS: The expression level of YKL-40 in prostate cancer tissues was significantly higher than that in adjacent tissues (P<0.01), and it was higher in DU145 cells than that in PC3 cells (P<0.05). The expression level of YKL-40 was positively correlated with cell migration and invasion. YKL-40 can regulate the expression of EMT related genes (Twist, Snail, Slug, N-cadherin, Vimentin and E-cadherin).

CONCLUSIONS: The expression level of YKL-40 was positively correlated with the migration and invasion of prostate cells, it affects cancer metastasis by regulating EMT.

Keywords: RT-PCR; YKL-40; epithelial mesenchymal transition (EMT); immunohistochemistry; prostate cancer; western blotting

Conflict of interest statement

None.

References

  1. J Hepatol. 2017 Feb;66(2):424-441 - PubMed
  2. J Biol Chem. 2011 Apr 29;286(17 ):15332-43 - PubMed
  3. Oncogene. 2005 Nov 14;24(50):7443-54 - PubMed
  4. Curr Opin Urol. 2009 May;19(3):315-21 - PubMed
  5. Int J Cancer. 2011 Mar 15;128(6):1316-26 - PubMed
  6. World J Gastrointest Oncol. 2017 Jan 15;9(1):37-41 - PubMed
  7. Leuk Lymphoma. 2015 ;56(8):2476-8 - PubMed
  8. Urol J. 2012 Summer;9(3):568-73 - PubMed
  9. Oncogene. 2014 Apr 17;33(16):2110-22 - PubMed
  10. CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32 - PubMed
  11. Lancet. 2001 Feb 3;357(9253):336-41 - PubMed
  12. Future Oncol. 2009 Oct;5(8):1169-79 - PubMed
  13. Hum Pathol. 2000 May;31(5):578-83 - PubMed
  14. Int J Cancer. 2012 Jul 15;131(2):377-86 - PubMed
  15. Mol Cancer. 2017 Jan 30;16(1):8 - PubMed
  16. J Neuroimmunol. 2016 Mar 15;292:52-7 - PubMed
  17. Cancer. 2010 Jun 1;116(11):2688-97 - PubMed
  18. J Immunol. 2013 Jan 1;190(1):438-46 - PubMed
  19. Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):194-202 - PubMed
  20. Hum Cell. 2017 Jan;30(1):1-10 - PubMed
  21. Front Physiol. 2013 May 28;4:122 - PubMed
  22. Mol Cancer Ther. 2011 May;10 (5):742-51 - PubMed
  23. Arch Gynecol Obstet. 2017 Apr;295(4):817-825 - PubMed
  24. J Leukoc Biol. 2015 Dec;98 (6):931-6 - PubMed

Publication Types